Carl Kirkpatrick

Professor

MONASH UNIVERSITY

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Carl Kirkpatrick is a faculty member at Monash University in Australia. His research focuses on pharmacokinetics, pharmacogenomics, and the application of innovative methodologies in medication management, particularly in pediatric populations and specific clinical conditions. Recent articles authored by Professor Kirkpatrick include studies on the pharmacokinetics of drugs in cystic fibrosis patients, the quantitation of oxytocin in clinical settings, and the implications of pharmacogenomics on cancer treatment outcomes.

Articles (16)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Catherine Bendel

University of Minnesota

UNITED STATES

View details

Daryl Jones

AUSTRALIA

View details

Christoph Hornik

Asssociate Professor

Duke University

UNITED STATES

View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA

View details

Robert Stowe

Clinical Professor

The University of British Columbia

CANADA

View details

Daniel Gonzalez

Duke University

UNITED STATES

View details

Joseph A. Nicolazzo

MONASH UNIVERSITY

AUSTRALIA

View details

Pete Lambert

Monash University Malaysia.

AUSTRALIA

View details

D. James Cooper

MONASH UNIVERSITY

AUSTRALIA

View details

Kenan Gu

National Institutes of Health

UNITED STATES

View details

Chad Bousman

Associate Professor

University of Calgary

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Carl Kirkpatrick

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study

Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients With Cystic Fibrosis

A systematic review and meta‐analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer

Characterizing Enoxaparin’s Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population

Application of immunocapture and nanoflow LC–MS/MS to overcome the barriers to the quantitation of oxytocin in plasma of women in third stage labour

Virtual twins for model‐informed precision dosing of clozapine in patients with treatment‐resistant schizophrenia

Medication-related Medical Emergency Team activations: a case review study of frequency and preventability

Pharmacokinetics and safety of inhaled oxytocin compared with intramuscular oxytocin in women in the third stage of labour: A randomized open‐label study

Exploring the role of ex vivo metabolism on blood and plasma measurements of oxytocin among women in the third stage of labour: A post hoc study

An evaluation of the Australian Community Pharmacy Agreement from a public policy perspective: industry policy cloaked as health policy?

Consistent terminology for medication-related problems in pharmacogenomic cases.

Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.

Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study.

Rescue Everolimus Post Lung Transplantation is Not Associated With an Increased Incidence of CLAD or CLAD-Related Mortality.

Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination.

Collaborators (11)

Catherine Bendel

Daryl Jones

Christoph Hornik

Paul James

Robert Stowe

Daniel Gonzalez

Joseph A. Nicolazzo

Pete Lambert

D. James Cooper

Kenan Gu

Chad Bousman

Make your next move.